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PCR for the detection of botulinum neurotoxin gene types A to E was used in the investigation of a case of
equine botulism. Samples from a foal diagnosed with toxicoinfectious botulism in 1985 were reanalyzed by PCR
and the mouse bioassay in conjunction with an environmental survey. Neurotoxin B was detected by mouse
bioassay in culture enrichments of serum, spleen, feces, and intestinal contents. PCR results compared well
with mouse bioassay results, detecting type B neurotoxin genes in these samples and also in a liver sample.
Other neurotoxin types were not detected by either test. Clostridium botulinum type B was shown to be prevalent
in soils collected from the area in which the foal was raised. Four methods were used to test for the presence
of botulinum neurotoxin-producing organisms in 66 soil samples taken within a 5-km radius: PCR and agarose
gel electrophoresis (types A to E), PCR and an enzyme-linked assay (type B), hybridization of crude alkaline
cell lysates with a type B-specific probe, and the mouse bioassay (all types). Fewer soil samples were positive
for C. botulinum type B by the mouse bioassay (15%) than by any of the DNA-based detection systems.
Hybridization of a type B-specific probe to DNA dot blots (26% of the samples were positive) and
PCR-enzyme-linked assay (77% of the samples were positive) were used for the rapid analysis of large numbers
of samples, with sensitivity limits of 3 x 106 and 3,000 cells, respectively. Conventional detection of PCR
products by gel electrophoresis was the most sensitive method (300-cell limit), and in the present environ-
mental survey, neurotoxin B genes only were detected in 94% of the samples.
Toxicoinfectious botulism in horses presents clinically as
progressive neuromuscular paralysis. Horses of all ages are
susceptible, but the disease most commonly occurs in fast-
growing foals at 2 to 4 weeks of age (9). The condition,
previously referred to as "shaker foal syndrome," was first
described in 1967 (7). The etiologic mechanism of the disease
remained obscure until it was established experimentally that
Clostridium botulinum infection of necrotic lesions such as
gastric ulcers and foci of necrosis in the liver and subsequent
intoxication caused the disease syndrome (10).
Laboratory confirmation of toxicoinfectious botulism is of-
ten difficult, and the diagnosis is usually based on clinical
presentation alone. Direct testing of serum samples from
affected animals for toxin often yields negative results in the
mouse bioassay, presumably because circulating toxin is bound
quickly at the neuromuscular junction and the serum contains
only a minute amount of toxin that usually cannot be detected
by conventional methods (9). C. botulinum has been isolated
from feces, gastric ulcers, and areas of necrosis in the livers,
spleens, lungs, skin, and muscles of diseased animals (9). The
presence of other bacteria in feces and necrotic lesions often
prevents the isolation of C. botulinum and detection of the
neurotoxin in the mouse bioassay.
Contaminated soil and fecal material are the likely sources
of the organism. The type of C. botulinum involved in out-
breaks of equine botulism seems to correlate with the geo-
* Corresponding author. Mailing address: Department of Microbi-
ology, University of Queensland, Queensland 4072, St. Lucia, Austra-
lia. Phone: 61 7 365 4641. Fax: 61 7 365 4620. Electronic mail address:
Trish@biosci.uq.edu.au.
graphic prevalence of a specific type in the region. MacKay and
Berkhoff (4) reported on the incidence of type C equine
botulism in Florida and the isolation of C. botulinum type C in
soils and sediments in that region. C. botulinum type B is
prevalent in the Kentucky area, where numerous cases of type
B toxicoinfectious botulism have been reported (9). This
disease has been reported in horse studs on the Darling
Downs, approximately 130 km west of Brisbane, Queensland,
Australia (6, 13). In 1985, a 17-day-old foal with signs of
botulism was received at the Animal Research Institute at
Yeerongpilly. C. botulinum type B was isolated from the foal's
intestinal contents and feces. A head lesion yielded a similar
isolate not confirmed to be C. botulinum type B because of low
toxicity in the mouse bioassay.
The purpose of the study described here was to reanalyze
this case of equine botulism by using DNA-based methods for
the detection of C. botulinum neurotoxin genes and to compare
these methods with the conventional mouse bioassay. Soil
samples taken from the Darling Downs region were tested to
determine the prevalence of C. botulinum. PCR and ethidium
bromide-stained agarose gel electrophoresis for the visualiza-
tion of amplified PCR products were compared with PCR and
then an enzyme-linked assay (PCR-ELA) (2). The latter is a
simplified protocol for the detection ofPCR products suited to
the screening of a large number of samples.
MATERIALS AND METHODS
Bacteria. The strains which were used in the study are listed
in Table 1. All clostridial isolates were inoculated into cooked
meat medium (CMM; Oxoid) rehydrated with either trypticase
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TABLE 1. Isolates used in the study and their toxin production
Species Toxina Reference Sourceb
Clostridium botulinum A ATCC 441C ATCC
A726
Clostridium butyricum
Clostridium botulinum
Clostridium baratii
Clostridium argentinense
Clostridium tetani
NCTC 7273
A625, A688, A777, A805
ARI J6621-11, ARI P8568-3A, CSL 1787
17B
NCTC 8264, NCTC 3732
M91, Oderstepoort
NCTC 8265
ATCC 17855
Abashiri, Alaska, Beluga, EK, Iwannai,
Minneapolis, Rakefisk, VH, 16/63
ATCC 43755
NCTC 10281
ATCC 43756
ACM 3690
ACM 58
ACM 54, ACM 60
ACM 349
ACM 55
I A* ,%_
ACH
NCTC
ACH
ARI
CSIRO
NCTC
ARI
NCTC
ATCC
IFR-UK
ATCC
NCTC
ATCC
ACM
ACM
ACM
ACM
ACM
Clostridium butyricum
Bacillus cereus
ACM 2646 ACM
ATCC 14579
Listeria innocua
ATCC
ACM 3178
Listenia monocytogenes
Escherichia coli
ACM
ACM 527 ACM
ACMACM 1803
a Only clostridial neurotoxins are recorded.b ATCC, American Type Culture Collection; ACH, Adelaide Children's Hospital, Adelaide, Australia; NCTC, National Collection of Type Cultures, London, United
Kingdom; ARI, Animal Research Institute, Yeerongpilly, Australia; IFR-UK, Institute of Food Research, Reading Laboratory, Reading, United Kingdom; ACM,
Australian Collection of Microorganisms, Brisbane, Australia.
c ATCC Deaccessioned from the American Type Culture Collection in 1964; available as strain NCTC 88738.
peptone yeast extract glucose cysteine (TPYGC) broth (3) or
peptone yeast extract glucose (PYG) (12). Proteolytic isolates
were incubated at 37°C and nonproteolytic strains were incu-
bated at 30°C for 24 to 48 h. When cooked meat granules were
omitted from the broth, anaerobic conditions were established
by using H2-CO2-generating envelopes placed in anaerobic
jars (BBL GasPak systems). Nonclostridial isolates were grown
in PYG broth or on nutrient agar plates (Oxoid) aerobically at
37°C for 24 h. DNA was extracted as described previously (11).
Animal and soil samples. Autopsy samples from a 17-day-
old foal with signs of toxicoinfectious botulism had been stored
at -20°C since 1985 at the Animal Research Institute,
Yeerongpilly. The animal presented with signs including mus-
cular tremors, unsteady gait, inability to rise unaided, paralysis
of the tongue with inability to swallow, dilated pupils, and
respiratory distress. The samples examined in the present
investigation were the intestinal contents, feces, liver, spleen,
serum, and a head lesion swab. Two grams of each specimen
was added to 20 ml ofCMM rehydrated with TPYGC for 48 h
at 320C.
Soil samples were collected from three horse studs (proper-
ties 1 to 3) in the Darling Downs area with a history of
toxicoinfectious botulism (5) and one property (property 4) on
which horses were not bred and which had no recorded cases
of botulism. Six samples were taken from one paddock on
property 1, 5 samples were taken from one paddock on
property 2, 30 samples were taken from five fields on property
3, and 25 samples were taken from five paddocks on property
4. Approximately 100-g samples, taken with a trowel from 10
cm below the turf, were placed in sterile plastic bags, sealed,
and transported to the laboratory. Ten grams of each soil
sample was added to 90 ml of TPGYC broth, and the mixture
was incubated for 48 h at 320C.
The liquid broth of culture enrichments from all specimens
B
C
D
E
E
E
F
F
G
Tetanus
Clostridium sporogenes
Clostridium novyi type A
Clostridium perfringens
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TABLE 2. Oligonucleotide primers selected for neurotoxin types A to E
Type Primer Sequence Regiona T. (oC)b
A Al 5'-TATGGAATAGCAA7TAATCC-3' 697-1154 (457) 47
A2 5'-GTGTAATTTllACCTllAGGTAC-3' 49
B B3 5'-AGATAGACGTGT7CCACTCG-3' 414-1141 (727) 55
B4 5'-CTGCTATATrAGITTTCTG-3' 43
C C1 5'-ATATACTCCGGTTACGGCG-3' 1353-2351 (998) 53
C2 5'-CCTGGATAACCACGTTCCC-3' 55
D Dl 5'-TAAGTAAACCGCCCAGACC-3' 220-623 (403) 53
D2 5'-TAGTATAGATAATGTICCA-3' 43
E El 5'-TATATA7TAAACCAGGCGG-3' 283-728 (445) 47
E2 5'-TAGAGAAATATTGGAACTG-3' 45
"Region refers to the position of the first and last nucleic acid in the targeted fragment, and the size (in parentheses) refers to the number of nucleotides that
comprise the fragment.
b The melting temperature (Tm) was calculated by the following formula: Tm = [4°C(G+C content of oligonucleotide) + 2°C(A+T content of oligonucleotide)] -
5°C (1).
was centrifuged at 3,500 x g for 15 min to sediment the
particulate matter, including bacterial cells, and the particulate
matter was held for PCR analysis and DNA dot blot hybrid-
izations. The supernatants were collected and examined im-
mediately for the presence of any botulinum toxins by using the
mouse bioassay as described by the Standards Association of
Australia (8).
DNA amplification and colorimetric detection of PCR prod-
ucts. DNA was extracted from the cell pellets of sample
enrichments by a simple alkaline lysis procedure, and both
DNA extraction and PCR for neurotoxin genes A and C to E
proceeded as described previously (11). All oligonucleotide
primers (Table 2) were synthesized either by the Queensland
Institute of Medical Research or at the University of Queens-
land Centre for Molecular Biology and Biotechnology. Primers
specific for neurotoxin type B were synthesized by Bresatec
Ltd., Adelaide, Australia, for use with the PCR-ELA detection
protocol. Primer B3.1 had the same sequence as primer B3
except for a DNA-binding protein recognition sequence at-
tached to the 5' end (GGATGACTCA + primer B3), while
primer B4.1 was identical to primer B4 with a biotin moiety at
the 5' end (biotin + B4). Optimization of the PCR format and
the specificity and sensitivity of the B3.1-B4.1 primer pair were
determined by previously described procedures (11), and PCR
was evaluated by both agarose gel electrophoresis and PCR-
ELA.
The colorimetric analysis of PCR products (PCR-ELA) was
performed according to the manufacturer's instructions (Cap-
tagene-GCN4; AMRAD Corporation Ltd., Melbourne, Victo-
ria, Australia). The DNA-binding protein recognition se-
quence incorporated in primer B3.1 allowed amplified DNA to
be bound to wells of a microtiter dish coated with the protein
GCN4. The bound DNA could then be detected colorimetri-
cally by using avidin-peroxidase, which binds to the biotin label
incorporated into the PCR product via primer B4.1. Results
were interpreted by eye or with a microtiter plate reader
(Titertek Multiskan MCC/340) according to the manufactur-
er's instructions.
Hybridization with a specific probe. DNA dot blots were
prepared by using a microfiltration apparatus (Bio-Rad) ac-
cording to the manufacturer's instructions. Two hundred mi-
croliters of alkaline cell lysate of soil enrichment samples, held
at room temperature for 5 min, were neutralized with an equal
volume of 2 M ammonium acetate (pH 7.0). DNA was
transferred to a nylon membrane pretreated with 1 M ammo-
nium acetate. The filter was air dried and the DNA was fixed
to the membrane by exposure to UV light for 3 min. A
digoxigenin-labelled probe specific for neurotoxin type B (11)
was used for hybridization. Hybridization was carried out at
65°C for 4 h. The hybridization solution contained 100 ng of
probe per ml. Posthybridization washes and visualization of the
probe-target hybrid were done in accordance with the manu-
facturer's instructions. Sensitivity was determined by hybrid-
ization of the type B probe to DNA dot blots of various
amounts of C. botulinum NCTC 7273 type B genomic DNA
(100 ng to 1 fg).
RESULTS
Specificity and sensitivity of primers B3.1-B4.1 and neuro-
toxin B probe. The reaction conditions for B3.1-B4.1 primers
that gave the optimal sensitivity and specificity required 20
pmol of each primer, 3.0 mM MgCl2, and annealing, extension,
and denaturation temperatures and times of 55°C and 20 s,
60°C and 2 min, and 90°C and 20 s, respectively, for 25 cycles.
The specificity of the B3.1-B4.1 primer pair was assessed by
using purified DNA extracted from neurotoxic clostridial
strains, nontoxic clostridial species, and unrelated strains (Ta-
ble 1). Only the DNAs from strains of C. botulinum type B
produced positive PCR results that were detected by agarose
gel electrophoresis (data not shown) and PCR-ELA (Fig. 1).
Nonspecific amplification products were not detected follow-
ing gel electrophoresis following PCR at DNAs from genotyp-
ically related microorganisms or different genera (data not
shown).
Serial 10-fold dilutions of genomic DNA from C. botulinum
type B were used to determine the sensitivities of PCR and gel
electrophoresis, PCR-ELA, and DNA dot blot hybridizations
for the detection of neurotoxin B genes. The level of sensitivity
observed following DNA amplification and gel electrophoresis
was 1 pg. The lowest amount of template that produced an
observable color reaction in the ELA after the optimal number
of PCR cycles was 10 pg. Only 10 ng of DNA was detected by
using the type B-specific probe. No false-positive reactions that
could be attributed to molecular contamination with DNA or
the constituents of the enrichment medium were observed.
Given that the molecular mass of C. botulinum is 1.8 x 109 Da
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FIG. 1. Detection of botulinum neurotoxin type B PCR products
by an ELA (Captagene-GCN4; Amrad). Row A, reactions with DNAs
from C. botulinum type A ATCC 441 (position 1); C. botulinum type B
strains NCTC 7273 (position 2), 17B (position 3), A625 (position 4),
A688 (position 5), A777 (position 6), A805 (position 7), ARI J6621-11
(position 8), ARI P8568-3A (position 9), and CSL 1797 (position 10);
C. botulinum type C NCTC 8264 (position 11); and C. botulinum type
D M91 (position 12). Row B, reactions with DNAs from C. botulinum
type E ATCC 17855 (position 1), C. butyricum type E ATCC 43755
(position 2), C. botulinum type F NCTC 8265 (position 3), C. baratii
type F ATCC 43756 (position 4), C. argentinense ACM 3690 (position
5), C. tetani ACM 58 (position 6), C. novyi type A ACM 349 (position
7), C. sporogenes ACM 54 (position 8), C. perfringens ACM 55 (position
9), C. butyricum ACM 2646 (position 10), B. cereus ATCC 14579
(position 11), and L. innocua ACM 3178 (position 12). Row C,
reactions with DNAs from L. monocytogenes ACM 527 (position 1), E.
coli ACM 1803 (position 2), positive plate control (position 3),
negative plate control (position 4), negative PCR control (position 5),
soil samples from Darling Downs property 4, field 1 (positions 6 to 10),
field 2 (positions 11 and 12). Row D, reactions with DNAs from
Darling Downs property 4, field 2 (positions 1 to 3), field 3 (positions
4 to 8), and field 4 (positions 9 to 12). Row E reactions with DNAs
from Darling Downs property 4, field 4 (position 1) and field 5
(positions 2 to 6) and property 1 (positions 7 to 12). Row F, reactions
with DNAs from property 2 (positions 1 to 5) and property 3, field 1
(positions 6 to 10) and field 2 (positions 11 and 12). Row G, reactions
with DNAs from property 3, field 2 (positions 1 to 8) and field 3
(positions 9 to 12). Row H, reactions with DNAs from property 3, field
3 (position 1), field 4 (positions 2 to 6), and field 5 (positions 7 to 11);
position 12 is a blank well. The detection system was specific for pure
cultures of C. botulinum type B only. No cross-reactions with other
organisms were observed.
(1), theoretically, PCR and gel electrophoresis could detect
300 type B cells and PCR-ELA could detect 3,000 type B cells.
Original laboratory results. In 1985, samples were exam-
ined, without enrichment, for C. botulinum toxin by the mouse
bioassay, with negative results (Table 3). Bacteria with mor-
phological and biochemical features of C. botulinum were
simultaneously isolated from intestinal contents, feces, and
head lesion enrichments. Culture supernatants of the isolates
from the intestinal contents and feces killed mice, which had
characteristic signs of botulism, and the toxicity was neutral-
ized by antitoxin to type B but not antitoxin to type A, C, D, or
E. Mice injected with culture supernatant from the head lesion
isolate showed signs of botulism but did not die, and antitoxin
tests were not done.
Retesting of stored samples. Anaerobic bacterial growth was
observed in all sample enrichments with the exception of the
head lesion material. Positive mouse bioassay results were
observed when culture supernatants of serum, feces, spleen,
TABLE 3. Detection of C. botulinum type B in autopsy samples
from a foal with toxicoinfectious botulism by PCR
and the mouse bioassay
1985 results 1992 results
Sample Direct Toxin
toxin Isolationb type B bosa PCR'
testing' confirmedc bioassa/'
Feces - + + + +
Head lesion NTf +
Intestinal contents - + + + +
Liver NT - A - +
Serum - - NA + +
Spleen NT - NA + +
C. botulinum type B + +
(control)
aDirect testing of a sample for botulinum neurotoxin by the mouse bioassay.b Isolation of an organism resembling C. botulinum.
cConfirmation of neurotoxin type B production from the culture supernatant
of a suspect isolate.
d Detection of neurotoxin following sample enrichment by the mouse bioassay.
Detection of type B neurotoxin genes by PCR.
f NT, not tested.
g NA, not applicable.
and intestinal content enrichments were used (Table 3). The
PCR protocol was able to detect the presence of type B
neurotoxin genes in these samples and additionally from the
liver enrichment (Table 3; Fig. 2). Other neurotoxin types were
not detected in the samples by either PCR (types A to E only)
or the mouse bioassay (all types). Negative and positive
controls reacted accordingly.
Soil sampling. C. botulinum type B was detected by PCR and
agarose gel electrophoresis, PCR-ELA, hybridization with a
type B-specific probe, and the mouse bioassay on properties 1,
3, and 4 (Table 4). Only the two PCR-based methods detected
the organism on property 2 (Table 4). PCR and gel electro-
phoresis were the most sensitive methods, detecting C. botuli-
num type B in 94% of the samples; this was followed by
PCR-ELA (77%), probing of DNA dot blots of crude alkaline
cell lysates with the type B-specific probe (26%), and the
mouse bioassay (15%) (Table 4). Definitive positive or nega-
tive results were not obtained by the mouse bioassay for more
than two-thirds of the soil sample enrichments either because
reproducible symptoms were not observed or because neutral-
E
E 1 2 3 4 5 6 7
727b,3-oE
FIG. 2. PCR detection of type B botulinum neurotoxin genes in
autopsy samples from a foal with clinical symptoms of toxicoinfectious
botulism. The molecular mass marker (MWM) was a commercially
available 1-kb DNA ladder (Bethesda Research Laboratories). The
amount of material loaded into each well of the gel represented 1/10th
of the PCR mixture volume. The samples were a positive PCR control
(lane 1), feces (lane 2), intestinal contents (lane 3), liver (lane 4), head
lesion (lane 5), serum (lane 6), and spleen (lane 7). Only the head
lesion sample produced negative PCR results.
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TABLE 4. Occurrence of C. botulinum type B in soil samples from
four properties in the Darling Downs region
% Positive by the following detection method
Property no.' Hybridization Mouse
PCR PCR-ELA with type B bioassay
probe
1 (n = 6) 100 67 34 17
2 (n = 5) 100 80 0 0
3 (n = 30) 100 87 37 20
4 (n = 25) 84 68 16 12
Total (n = 66) 94 77 26 15
a n denotes the number of samples.
izations could not be confirmed from successive tests. No other
neurotoxin types were detected by PCR or the mouse bioassay.
DISCUSSION
Toxicoinfectious botulism in foals has been clinically diag-
nosed in horses from horse farms in a well-defined area of the
Darling Downs region for the past 27 years. Between 1967 and
1977 on one particular thoroughbred horse farm, 91 cases
occurred among foals, yearlings, and adult horses, which
showed typical clinical signs of botulism, and only two animals
survived (6). Several foals autopsied at the end of the period
were found to be infected with C. botulinum type B (13). On
the basis of these observations, a vaccine for C. botulinum type
B was developed and administered to mares prior to foaling
(13). Examination of soil samples from the region in the
present study confirmed a prevalence of C. botulinum type B.
Other neurotoxin types were not detected by PCR or mouse
bioassay, indicating that the use of a monovalent type B
vaccine was appropriate in this area. We used PCR and the
mouse bioassay to reexamine a foal from the region with a
clinical diagnosis of botulism. When this foal was first investi-
gated in 1985, microbial analysis of autopsy samples from the
foal supported the clinical diagnosis of botulism by isolation
and subsequent confirmation in the mouse bioassay of C.
botulinum type B from the intestinal contents and feces. Upon
reexamination of the specimens in the present study, the
mouse bioassay again detected the organism in enrichments
from the intestinal contents and feces and, in addition, in
enrichments from the spleen and serum. PCR results com-
pared well with those of the mouse bioassay. A discrepancy was
observed with the liver sample, which was positive by PCR but
negative by the mouse bioassay. Head lesion samples that in
1985 produced signs of botulism in mice but that were not
lethal were negative upon retesting by both methods. The
integrity of the PCR was confirmed because no DNA carryover
effects were detected. From the results of the present study, we
conclude the PCR is a sensitive method in comparison with the
mouse bioassay for the detection of C. botulinum.
An unexpected observation was the detection of C. botuli-
num in serum samples by both PCR and the mouse bioassay.
Botulinum neurotoxin is rarely detected in the serum of horses
with toxicoinfectious botulism (9). However, serum is not
usually enriched prior to the mouse bioassay, and this may
explain the discrepant result on retesting. Serum would contain
fewer contaminating bacteria than necrotic lesions, which are
usually used in the microbial investigation of horse botulism
cases. The analysis of serum both directly and following
enrichment should be considered an alternative diagnostic
approach for future investigations of suspected cases of this
disease.
Studies of the environment in Australia in the past have
concluded that there is a low prevalence of or no C. botulinum.
The lack of detection of the organism may have been due to
the sensitivity of the mouse bioassay used. In the present
environmental survey, fewer soil samples were positive for C.
botulinum type B by the mouse bioassay than by any of the
DNA-based detection systems. Inconclusive bioassay results
were obtained with 66% of the samples. Reproducible results
could not be obtained from successive mouse bioassays, pre-
sumably because of the effects of unknown interfering sub-
stances present in the natural soil sample. The mouse bioassay
results, however, confirmed the presence of C. botulinum type
B on three of the properties from which soil samples were
obtained, including the one farm without a history of horse
botulism.
The number of soil samples positive by each DNA-based
method reflected the order of sensitivity of each test. Conven-
tional detection of PCR products by gel electrophoresis was
the most sensitive method, and in the soil survey, 94% of the
samples contained the genes for neurotoxin B; this was fol-
lowed by PCR-ELA, which detected type B neurotoxin genes
in 77% of the samples, and direct probing of crude cell lysates,
the least sensitive technique, which detected type B neurotoxin
genes in only 26% of the samples, which was slightly better
than the mouse bioassay results. However, unlike the mouse
bioassay, the results from PCR-based methods were reproduc-
ible in three successive tests and after 6 months of storage of
the purified DNA extract (data not shown). Of the three
DNA-based detection methods used, hybridization of the type
B-specific probe to DNA dot blots and PCR-ELA were
particularly suited for the analysis of large sample numbers. By
PCR-ELA, up to 96 DNA amplifications were analyzed on a
single microtiter plate within 2 h, which was more rapid than
the DNA blot hybridization techniques and analysis of that
number of PCR products by gel electrophoresis. Results were
easily distinguished by eye and were confirmed spectrophoto-
metrically. Although a convenient method for mass screening,
PCR-ELA was less sensitive than the visualization of PCR
products by gel electrophoresis, which remains the preferred
procedure, especially when detection of small spore numbers is
expected. Attempts were made to improve the sensitivity of
ELA detection of PCR products by increasing the DNA
binding time from 30 to 60 min and then 90 min, without
success (data not shown).
The environmental survey described here provided the
opportunity to compare PCR with the mouse bioassay. Unfor-
tunately, components of the soil samples interfered with the
bioassay, and inconclusive results were obtained from two-
thirds of the samples. The mouse bioassay is considered the
standard with which to compare new methods; however, that
bioassay is not suitable for use on environmental samples.
Nevertheless, our results demonstrate that PCR is a conve-
nient alternative for the detection of C. botulinum from
environmental samples. Use of both PCR and the mouse
bioassay demonstrated the prevalence of C. botulinum type B
in the soils of properties where equine botulism cases had
occurred and in those of properties with no history of botulism.
A more extensive quantitative survey for C. botulinum in soils
in areas used for horse breeding and those used exclusively for
agricultural purposes and a survey of animal husbandry prac-
tices on the properties used for horse breeding are now
required. This would help to determine how widespread the
bacterium is in the Darling Downs region and the potential risk
factors associated with the disease.
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